This Article Full Text (OnlineFirst PDF) All Versions of this Article: 0148607108322395v1 33/1/55    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Putchakayala, K. Articles by Fryer, J. Search for Related Content PubMed PubMed Citation Articles by Putchakayala, K. Articles by Fryer, J. Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?

An Evaluation of Model for End-stage Liver Disease and Serum C-reactive Protein as Prognostic Markers in Intestinal Failure Patients on PN

¹ Department of Surgery, Northwestern University Feinberg School of Medicine
² Kovler Organ Transplant Center, Northwestern Memorial Hospital
³ Department of Pediatrics, Northwestern University Feinberg School of Medicine
⁴ Department of Internal Medicine, Northwestern University Feinberg School of Medicine
⁵ Northwestern Memorial Hospital, Northwestern University

^* To whom correspondence should be addressed. E-mail: JFryer{at}nmh.org.

	Abstract

Background: Intestinal failure (IF) patients require parenteral nutrition (PN) to avoid malnutrition and death. However, they face complications of recurrent sepsis and liver failure. By the time liver failure is discovered, it is often too late for intervention and prognosis on the waiting list is grim. The Model for End-Stage Liver Disease (MELD) has traditionally been used to predict mortality in patients with liver failure but has never been analyzed in IF patients who are at risk for liver complications. C-reactive protein (CRP) is an acute inflammatory marker that has been shown to reflect disease progression in nonalcoholic steatohepatitis, a disease that in many ways resembles PN-associated liver disease. MELD and CRP are promising clinical markers of disease progression in IF patients on PN. Methods: The authors performed a retrospective, case-control study to compare levels of MELD and CRP within the entire population of 133 adult patients referred to Northwestern Memorial Hospital for IF from 1999 to 2006. Results: Elevated MELD score is strongly predictive of increased mortality over the subsequent 6 months. Elevated CRP is strongly predictive over a smaller 3-month window. One-year mortality was significantly greater in patients who have either elevated MELD scores or serum CRP levels. Conclusions: In this study, the authors evaluated for the first time use of MELD and serum CRP as predictive markers of mortality in IF patients. Both seem to be promising clinical tools to identify which patients are at highest risk for complication. (JPEN J Parenter Enteral Nutr. XXXX;XX:xx-xx)

First published on October 21, 2008, doi:10.1177/0148607108322395

Journal of Parenteral and Enteral Nutrition 2009;33:55.

A more recent version of this article appeared on January 1, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?